Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17β-estradiol and medroxyprogesterone acetate in postmenopausal women

Thrombosis and Haemostasis

Volumn 84, Issue 4, 2000, Pages 695-700

  Bar, J ^a   Lahav, J ^a   Hod, M ^a   Ben Rafael, Z ^a   Weinberger, I ^a   Brosens, J ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Estrogen; HRT; Menopause; Platelets; Progesterone

Indexed keywords

4 HYDROXYTAMOXIFEN; ADENOSINE TRIPHOSPHATE; ESTRADIOL; FULVESTRANT; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; STEROID RECEPTOR;

ADULT; ARTICLE; BINDING COMPETITION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; POSTMENOPAUSE; PRIORITY JOURNAL; STEROID BINDING; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 0033786970     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614089     Document Type: Article

References (52)

1. Sex differences in coronary heart disease: Why are women so superior? The 1995 Ancel Keys Lecture
2. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women
3. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study
4. Hormone therapy to prevent disease and prolong life in postmenopausal women
5. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
6. Effects of estrogen on estrogen/progestin regimens on heart disease risk factor in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions PEPI Trial
7. Postmenopausal hormone replacement therapy and cardiovascular disease
8. The protective effects of estrogen on the cardiovascular system
9. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
10. Estrogen and the blood vessel wall
11. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators
12. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A one year, double-blind, placebo-controlled study
13. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women
14. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
15. The pathogenesis of atherosclerosis: Part 1
16. The pathogenesis of coronary artery disease and the acute coronary syndromes
17. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits: Quantification of cellular proliferation by bromodeoxyuridine
18. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
19. Steroid and related receptors
20. Glucocorticoid receptor-like antigen in lymphoma cell membranes: Correlation to cell lysis
21. Cell surface localization of a novel nongenomic progesterone receptor on the head of human sperm
22. Identification of a specific binding protein for 1 alpha, 25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia
23. Interferon-inducible protein 10 and macrophage inflammatory protein-1 alpha inhibit growth factor stimulation of Raf-1 kinase activity and protein synthesis in a human growth factor-dependent hematopoietic cell line
24. Cell surface-binding sites for progesterone mediate calcium uptake in human sperm
25. Sperm-induced calcium oscillations of human oocytes show distinct features in oocyte center and periphery
26. Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional non-nuclear receptors
27. Phospholipase C beta and membrane action of calcitriol and estradiol
28. The effect of replacement therapy on platelet aggregation and ATP release in postmenopausal women
29. The effect of medroxyprogesterone acetate and clomiphene citrate on platelet function in menopausal women
30. The regulation of platelet aggregation in vitro by interleukin-1β and tumor necrosis factor-α: Changes in pregnancy and in pre-eclampsia
31. The relationship between affinity of progestins and antiprogestins for the progesterone receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: Evidence for heterospecific receptor modulation via the glucocorticoid receptor
32. The estrogen receptor -isoform (ER) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
33. Synergistic enhancement of PRB-mediated RU 486 and R 5020 agonist activities through cyclic adenosine 3',5'-monophosphate represents a delayed primary response
34. Atherosclerosis - An inflammatory disease
35. Aspirin and secondary mortality after myocardial infarction
36. Collaborative overview of randomized trials of anti-platelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients
37. Effect of estrogen and progesterone on platelet adhesiveness and aggregation in rabbits
38. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood. A beneficial effect on atherogenesis and thrombus formation?
39. Variability of integrin alpha2beta1 activity on human platelets
40. The estrogen receptor is present in human megakaryocytes
41. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells
42. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription
43. Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis
44. The risk of acute myocardial infarctions after estrogen and estrogen-progesterone replacement
45. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
46. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways
47. Characterization of high affinity progesterone-binding membrane proteins by anti-peptide antiserum
48. Inhibition of oxytocin receptor function by direct binding of progesterone